A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 9,879,250 shares of REPL stock, worth $123 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,879,250
Previous 9,236,057 6.96%
Holding current value
$123 Million
Previous $83.1 Million 30.26%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.09 - $11.23 $5.2 Million - $7.22 Million
643,193 Added 6.96%
9,879,250 $108 Million
Q2 2024

Aug 14, 2024

BUY
$5.01 - $9.46 $13.5 Million - $25.4 Million
2,687,127 Added 41.03%
9,236,057 $83.1 Million
Q1 2024

May 15, 2024

BUY
$6.87 - $9.31 $4.81 Million - $6.51 Million
699,679 Added 11.96%
6,548,930 $53.5 Million
Q4 2023

Feb 14, 2024

BUY
$6.75 - $16.18 $378,351 - $906,921
56,052 Added 0.97%
5,849,251 $49.3 Million
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $960,584 - $1.33 Million
60,187 Added 1.05%
5,793,199 $99.1 Million
Q2 2023

Aug 14, 2023

BUY
$15.65 - $24.1 $3.72 Million - $5.72 Million
237,396 Added 4.32%
5,733,012 $133 Million
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $7.53 Million - $12.5 Million
430,872 Added 8.51%
5,495,616 $97.1 Million
Q4 2022

Feb 14, 2023

BUY
$17.09 - $27.91 $15.3 Million - $24.9 Million
893,573 Added 21.42%
5,064,744 $138 Million
Q3 2022

Nov 14, 2022

SELL
$15.6 - $21.15 $26.7 Million - $36.2 Million
-1,711,360 Reduced 29.09%
4,171,171 $72 Million
Q2 2022

Aug 15, 2022

SELL
$13.32 - $19.98 $1.87 Million - $2.8 Million
-140,229 Reduced 2.33%
5,882,531 $103 Million
Q1 2022

May 16, 2022

BUY
$15.24 - $29.75 $2.35 Million - $4.59 Million
154,122 Added 2.63%
6,022,760 $102 Million
Q4 2021

Feb 14, 2022

BUY
$25.43 - $34.25 $3.86 Million - $5.19 Million
151,598 Added 2.65%
5,868,638 $159 Million
Q3 2021

Nov 15, 2021

BUY
$28.98 - $39.54 $18.8 Million - $25.6 Million
647,590 Added 12.77%
5,717,040 $169 Million
Q2 2021

Aug 16, 2021

BUY
$28.5 - $39.37 $56.7 Million - $78.4 Million
1,991,208 Added 64.69%
5,069,450 $195 Million
Q1 2021

May 17, 2021

BUY
$30.22 - $45.57 $13.7 Million - $20.6 Million
452,551 Added 17.24%
3,078,242 $93.9 Million
Q4 2020

Feb 16, 2021

BUY
$23.5 - $52.65 $61.7 Million - $138 Million
2,625,691 New
2,625,691 $100 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.